Phase 2 N=140 Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity
Nicotine Dependence
Primary: End-of-treatment Abstinence — 25; 13 Participants — p=0.011
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study
Food Hypersensitivity
Primary: Determine the Percentage of Subjects Who Demonstrate Sustained Unresponsiveness (SU) by a Negative Double-blind Placebo-controlled Food Challenge (DBPCFC). — 29…
Phase 2 N=21 Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
Hepatitis D
Primary: Number of Participants With Decline of Hepatitis Delta Virus (HDV) RNA Quantitative Measurements of >2 Logs From Baseline at 12 Weeks of Treatment — 1; 1; 1; 0…
Phase 2 N=255 A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Acute Myeloid Leukemia
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) at Phase 1B — 0; 0; 0; 0 Participants
Phase 2 N=49 Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System
Schizophrenia · Major Depressive Disorder · Bipolar I Disorder
Primary: Assessment of the Functionality of an Integrated Call Center for DMS by Adult Subjects With SCH, MDD, or BP1 Who Were Treated With Oral Aripiprazole. — 0; 0; 1; 8…
Phase 2 N=24 An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents
Cannabis Dependence
Primary: Feasibility of Recruitment, Measured by Number of Participants Recruited and Retained During Study Period — 24 Participants
Phase 2 N=116 Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Maximum Tolerated Dose (MTD) (Phase I) as Measured by the Number of Participants With Dose Limiting Toxicities — 0; 0; 1 Participants
Phase 2 N=41 Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer
Prostate Cancer
Primary: Metabolic Syndrome — 0; 0 kilograms
Phase 2 N=24 Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
Primary: Percentage of Subjects With Detectable Circulating T Cells After Treatment — 16.7 Percentage of participants
Phase 2 N=15 A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease
Graves' Disease
Primary: Percentage of Participants Whose Thyroid Stimulating Hormone (TSH) Levels Normalize After 12 Week Treatment — 0 percentage of participants
Phase 2 N=103 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
Anaemia
Primary: Change From Baseline in Hgb Levels at Day 29 — -0.61; -0.19; -0.13; 0.64 g/dL
Phase 2 N=59 Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
Primary: Rate of Major Molecular Response (MMR) at 6 Cycles for Ph+ CML CP Patients Resistant or Intolerant to Imatinib or Dasatinib — 39.4 Percentage of participants
Phase 2 N=45 Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL
Cataract
Primary: Percentage of Subjects With AC Cell Count of Zero on Day 7 — 3; 2 Participants
Phase 2 N=334 A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
Breast Cancer
Primary: Percentage of Participants With Objective Response (OR) by Centrally Assessed Breast Magnetic Resonance Imaging (MRI) Via Modified Response Evaluation Criteria in Solid…
Phase 2 N=190 Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons
AIDS
Primary: Geometric Mean Change in Human Immunodeficiency Virus Type 1 (HIV-1) Viral Load (VL) From Baseline — 1.0; 1.5; 1.3 RNA copies/mL